Press release
July 31, 2012
Gothenburg

Vitrolife's subsidiary in the USA has been sued

Vitrolife's subsidiary in the U.S.A., Vitrolife, Inc, has together with Southwest Transplant Alliance and University of Texas been sued for compensation by relatives to a patient who diseased after a lung transplantation in 2010.

Vitrolife's product for organ preservation (Perfadex) is claimed to have been used before the transplantation. Any number to the size of the claim has not been put forward.

Perfadex is an organ preservation solution that has been cleared by the FDA for the US market since 2001 and has to date been used in thousands of lung transplantations.

July 31, 2012
Gothenburg, Sweden
VITROLIFE AB (publ)
Thomas Axelsson
CEO

For further information, please contact:
Thomas Axelsson, CEO, +46 31 721 80 01
Magnus Nilsson, CEO Xvivo Perfusion AB, +46 31 721 80 61

Vitrolife is a global biotechnology/medical device Group that has business activities within the areas of fertility and transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 31, 2012 at 2:30 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.